Park2 Parkin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute | Value |
|---|---|
| Gene Symbol | PARK2 |
| Full Name | Parkin RBR E3 Ubiquitin Protein Ligase |
| Chromosomal Location | 6q26 |
| NCBI Gene ID | 5071 |
| Ensembl ID | ENSG00000185345 |
| UniProt ID | O60260 |
| OMIM | 602544 |
| Gene Family | RING finger family, RBR family |
| Protein Class | E3 ubiquitin ligase |
The PARK2 gene encodes Parkin, a RING-between-RING (RBR) family E3 ubiquitin ligase that plays a critical role in mitochondrial quality control through mitophagy[1]. Parkin is one of the most frequently mutated genes in autosomal recessive juvenile Parkinsonism (AR-JP), accounting for approximately 50% of familial PD cases and up to 20% of early-onset PD[2]. The protein is encoded by 12 exons spanning 1.4 Mb of genomic DNA, making it one of the largest Parkinson's disease genes[3]. Parkin functions as a key regulator of mitochondrial homeostasis, targeting damaged mitochondria for degradation via the autophagy-lysosome pathway[4].
Parkin contains several functional domains:
| Domain | Position | Function |
|---|---|---|
| Ubl domain | N-terminus (1-76) | Ubiquitin-like, auto-inhibition |
| RING0 | 141-217 | E2 binding, catalytic |
| RING1 | 237-328 | Ubiquitin transfer |
| IBR | 329-380 | Between RINGs |
| RING2 | 418-465 | Catalytic, Cys431 active site |
| REP | 466-494 | Repressor element |
Parkin catalyzes ubiquitin transfer through a unique mechanism:
| Substrate | Ubiquitin Linkage | Function |
|---|---|---|
| Mito proteins | K63, K27 | Mitophagy receptor |
| Pael-R | K48 | Proteasomal degradation |
| Synphilin-1 | K48, K63 | Protein aggregation |
| p53 | K48 | Apoptosis regulation |
| VDAC1 | K63 | Mitochondrial pore |
| Tomm20 | K27, K63 | Mitophagy |
PARK2 mutations are the most common cause of autosomal recessive juvenile Parkinsonism (AR-JP)[2]:
| Mutation Type | Examples | Frequency |
|---|---|---|
| Deletions | Exon deletions | 30-40% |
| Missense | R42P, C250F, T415N | 20-30% |
| Nonsense | Q34X, R245X | 10-15% |
| Splice site | IVS1+1G>A | 5-10% |
| Strategy | Approach | Status |
|---|---|---|
| AAV-PARK2 | Wild-type gene delivery | Preclinical |
| Small Molecule Activators | Parkin activators | Discovery |
| Autophagy Enhancers | mTOR-independent | Preclinical |
[1] Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608. PMID:9560156
[2] Luck CB, et al. PARK2 mutations in Parkinson's disease. J Neurol. 2020;267(10):2865-2875. PMID:32613488
[3] Mata IF, et al. Parkin: a multipurpose neuroprotective agent? Expert Opin Ther Targets. 2021;25(4):283-296. PMID:33945312
[4] Pickrell AM, et al. Beyond the mitochondrion: cytosolic PINK1 recruits parkin to regulate mitophagy. J Cell Biol. 2015;209(2):175-176. PMID:25901683
[5] Trempe JF, et al. Structure of parkin reveals mechanisms for activation. Cell. 2013;152(4):818-830. PMID:23352246
The study of Park2 Parkin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608. PMID:9560156
[2] Luck CB, et al. PARK2 mutations in Parkinson's disease. Journal of Neurology. 2020;267(10):2865-2875. PMID:32613488
[3] Mata IF, et al. Parkin: a multipurpose neuroprotective agent? Expert Opinion on Therapeutic Targets. 2021;25(4):283-296. PMID:33945312
[4] Pickrell AM, et al. Beyond the mitochondrion: cytosolic PINK1 recruits parkin to regulate mitophagy. Journal of Cell Biology. 2015;209(2):175-176. PMID:25901683
[5] Trempe JF, et al. Structure of parkin reveals mechanisms for activation. Cell. 2013;152(4):818-830. PMID:23352246